Erkki Ruoslahti

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Erkki Ruoslahti (b. 16 February 1940 in Imatra, Finland) is a cancer researcher and distinguished professor at Sanford Burnham Prebys Medical Discovery Institute and an adjunct distinguished professor at the University of California, Santa Barbara.[1] He moved from Finland to the United States in 1976.[2]

Ruoslahti made seminal contributions to biology of extracellular matrix and its receptors.[3] He discovered fibronectin, an adhesion molecule that helps make up connective tissues. He also introduced the concept of vascular "zip codes," the idea that each tissue bears molecular signatures that can be targeted by affinity ligands, and used in vivo peptide phage display to prove the concept and develop numerous tumor-homing peptides.[4] His group has developed a novel class of cell- and tissue-penetrating peptides that can be used for biological delivery of drugs and nanoparticles to extravascular space in tissues.[5][6] When exposed at the C-terminus of the peptide, such C-end Rule (CendR, pronounced "sender") peptides bind to neuropilin-1 and cause vascular leakage and tissue penetration. iRGD is a pan-tumor penetrating CendR peptide that can be used for tumor delivery of conjugated and combination delivery of various payloads (drugs or imaging agents, for example).[6][7][8][9]

Awards and honors[edit]


  1. ^ "Erkki Ruoslahti". Sanford Burnham Prebys Medical Discovery Institute. Retrieved March 14, 2013. 
  2. ^ Closing In on Cancer : In Search of a Cure, a La Jolla Research Center Reaches Into the Outer Limits Los Angeles Times
  3. ^ Ruoslahti, E.; Pierschbacher, M. (1987). "New perspectives in cell adhesion: RGD and integrins". Science. 238 (4826): 491–497. PMID 2821619. doi:10.1126/science.2821619. 
  4. ^
  5. ^ Teesalu, T.; Sugahara, K. N.; Kotamraju, V. R.; Ruoslahti, E. (2009). "C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration". Proceedings of the National Academy of Sciences. 106 (38): 16157. doi:10.1073/pnas.0908201106. 
  6. ^ a b Sugahara, K. N.; Teesalu, T.; Karmali, P. P.; Kotamraju, V. R.; Agemy, L.; Girard, O. M.; Hanahan, D.; Mattrey, R. F.; Ruoslahti, E. (2009). "Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors". Cancer Cell. 16 (6): 510–520. PMC 2791543Freely accessible. PMID 19962669. doi:10.1016/j.ccr.2009.10.013. 
  7. ^ "Cancer Drug Effectiveness Substantially Advanced". Archived from the original on May 7, 2010. Retrieved April 17, 2010. 
  8. ^ Sugahara, K. N.; Teesalu, T.; Karmali, P. P.; Kotamraju, V. R.; Agemy, L.; Greenwald, D. R.; Ruoslahti, E. (2010). "Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs". Science. 328 (5981): 1031–1035. PMC 2881692Freely accessible. PMID 20378772. doi:10.1126/science.1183057. 
  9. ^ Couzin-Frankel, Jennifer (8 April 2010). "New Peptide Helps Cancer Drugs Break Into Tumors". ScienceNOW. Archived from the original on June 8, 2013. Retrieved March 14, 2013. 
  10. ^ "Erkki Ruoslahti". United States National Academy of Sciences. Retrieved 14 March 2013.